Buy McDonald's!: Ag...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$6.19 -0.23 | -3.58%
02/08/12 - 02:45 PM ET
1.66M / 1.86M
Vol / Avg. Vol:6.41 / 6.42
Open / Prev. Close:6.14 - 6.48
Today's Range:3.94 - 12.82
52 Wk Range:36.64%
Performance YTD:TheStreet Rating:
Portfolios with EXEL
- Portfolio NameUser Type
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserASCO 2010
- UserBartwaldon Portfolio 1
- UserPART 3 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
Latest EXEL Headlines from TheStreet
- The Worst Biotech CEO of 2011 Is ... 12.09.11 | 07:12 am
- Exelixis Management Hosts Analyst Day - Conference Call Transcript 12.03.11 | 04:12 pm
- Exelixis' CEO Discusses At Piper Jaffray Health Care - Conference Call Transcript 11.30.11 | 07:11 pm
- Exelixis Stock Hits New 52-Week Low (EXEL) 11.21.11 | 10:11 am
- Biotech Stock Live Chat 11.17.11 | 11:11 am
- Exelixis Stock Hits New 52-Week Low (EXEL) 11.07.11 | 10:11 am
- Biotech Stock Mailbag: Prostate Cancer Drug Reaction 11.04.11 | 05:11 am
- Exelixis' CEO Hosts Special Conference - Conference Call Transcript 11.03.11 | 08:11 am
- Dendreon Risks Fading Into Irrelevancy 11.03.11 | 07:11 am
- Exelixis Stock Falls On Unusually High Volume (EXEL) 11.02.11 | 03:11 pm
Press Releases for EXEL
- Exelixis Announces February 8th Webcast Of Fourth Quarter & Full Year 2011 Financial Results Conference Call - Business Wire 02.06.12 | 07:02 pm
- Cabozantinib Shows Encouraging Activity In Heavily Pretreated Patients With Advanced Renal Cell Carcinoma - Business Wire 02.03.12 | 06:02 am
- Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data In Patients With Hepatocellular Carcinoma - Business Wire 01.20.12 | 02:01 pm
- Exelixis Licenses PI3K-Delta Program To Merck - Business Wire 12.21.11 | 06:12 am
- Exelixis Announces January 11 Webcast Of Presentation At The J.P. Morgan 30th Annual Healthcare Conference - Business Wire 12.14.11 | 05:12 pm
- Exelixis’ Cabozantinib Shows Encouraging Clinical Activity In Patients With Metastatic Breast Cancer - Business Wire 12.07.11 | 06:12 pm
- Reminder: Exelixis Announces Webcast Of Annual R&D Day On This Thursday, December 1 - Business Wire 11.29.11 | 06:11 am
- Exelixis Signs CRADA With National Cancer Institute To Expand Development Plan Of Cabozantinib - Business Wire 11.28.11 | 06:11 am
- Exelixis Announces November 29th Webcast Of Presentation At The Piper Jaffray Health Care Conference - Business Wire 11.22.11 | 06:11 am
- Exelixis Announces Initiation Of Phase 2 Investigator-Sponsored Trial Of Cabozantinib In Women With Hormone Receptor-Positive Metastatic Breast Cancer And Bone Metastases - Business Wire 11.21.11 | 06:11 am
Partner Headlines for EXEL
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- UPDATE: Piper Jaffray Downgrades Exelixis to Neutral - Benzinga 11.01.11 | 09:11 am
- Notable Put Options Activity in Exelixis - Benzinga 10.28.11 | 01:10 pm
- 3 Biotech Takeover/LBO Targets With Bullish Short Trends - Seeking Alpha 10.26.11 | 09:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- Biotech Gem Exelixis Is Compelling Only for the Long Term - Seeking Alpha 08.19.11 | 05:08 pm
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Exelixis extends timeline for thyroid cancer data - Reuters 07.06.11 | 04:07 pm
- Company News for June 07, 2011 - Corporate Summary - Zacks 06.07.11 | 10:06 am
